ClinicalTrials.gg
CompletedNCT00521339Updated May 7, 2020Results posted

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

A Phase 2 interventional study of Apremilast in Psoriasis-Type Psoriasis and Plaque-Type Psoriasis, sponsored by Amgen. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-07.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
32nd of 44
31 · median 103
Started
2007
the only one that year
Phase 2
10 of 44
none open now
Registered
1st of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 32nd largest by enrollment, is the only one that started in 2007, is one of 10 in phase 2, and was the 1st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.

Read the detailed description

This is a phase 2, multicenter, open-label, study to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy of Apremilast in participants with recalcitrant plaque-type psoriasis.

Approximately 31 participants were enrolled and received 20 mg apremilast orally BID and, in participants who are non-responders after 84 days of apremilast, 30 mg Apremilast over the course of the two study treatment phases. The study consisted of four phases: Screening Phase - up to 35 days, Treatment Phase of 84 days, Extension Phase of 84 days and a Observational Follow-up Phase of 28 days.

During the Treatment Phase, participants received two 20 mg Apremilast capsules each day. Following the Treatment Phase, participants had the option to continue on treatment during the Extension Phase. During the Extension Phase, participants either continued to take two 20 mg or dose escalated to two 30 mg of Apremilast each day. Participants who were considered responders (achieved a Psoriasis Area and Severity Index (PASI-75) at the beginning of the Extension Phase continued on 20 mg twice per day (BID) while the remaining participants received 30 mg capsules BID. The Extension Phase was introduced after some participants had already completed the study; therefore, there were several participants who never had the opportunity to continue into the Extension Phase. All participants were asked to participate in a 4-week post-treatment observational follow-up phase either upon completion of the study or upon discontinuation of study drug for those participants who terminated the study early.

03

Conditions studied

  • Psoriasis-Type Psoriasis
  • Plaque-Type Psoriasis

Browse trials for

Keywords

  • Apremilast,
  • Psoriasis,
  • PASI-75,
  • sPGA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Must understand and voluntarily sign an form

  • Must be male or female subject of any ethnic origin or race that is >18 years at time of consent
  • Must have a documented history of plaque-type psoriasis for at least 6 months prior to screening visit
  • Subjects must fulfill criteria outlined in at least one of the following clinical categories:

    • Unresponsive to standard systemic therapy, as defined by clinical history, in the investigator's opinion, i.e. inadequate response to one or more adequate treatment course (s) of standard systemic therapy
    • Intolerant to or cannot receive (e.g., to prescribe) standard systemic therapy or biological interventions for psoriasis
  • Must have a Static Physician Global Assessment (sPGA) score of at least 3 and a Body surface area (BSA) ≥ 10% at screening
  • Must meet the specified laboratory criteria:

    o Must be able to adhere to the study visit schedule and study protocol requirements

  • Females of (FCBP) must have a negative urine pregnancy test at screening (Visit 1). In addition, FCBP must agree to use two of the following adequate forms of methods such as oral, injectable, or implantable hormonal contraception; tubal ligation; intrauterine device; barrier contraceptive with spermicide or vasectomized partner while on study. A FCBP must agree to have pregnancy tests every 4 weeks while on study medication.
  • Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in sexual activity with FCBP

Exclusion criteria

Exclusion Criteria:

  • History of (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major disease
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Pregnant or lactating females
  • History of active tuberculosis (TB) infection within 3 years prior to the screening visit. Infections which occurred > 3 years prior to entry must have been effectively treated
  • History of incompletely treated latent (as indicated by a positive PPD [purified protein derivative] skin results) TB infection
  • Clinically significant abnormality on the chest x-ray (CXR) at screening
  • Psoriasis flare within 30 days of screening, as defined by protocol
  • Use of systemic therapy for psoriasis within 28 days of Visit 2 (Baseline).
  • Topical therapy as defined in the protocol Adalimumab, etanercept, efalizumab or infliximab use within 56 days of Visit 2 (Baseline)
  • Alefacept use within 180 days of Visit 2 (Baseline)
  • Phototherapy Ultraviolet light A (UVA), Ultraviolet light B (UVB), Psoralens and long-wave ultraviolet radiation (PUVA) within 28 days of Visit 2 (Baseline)
  • Use of any drug within 28 days of Visit 2 (Baseline), or 5 half lives if known (whichever is longer) Clinically significant abnormality on 12-lead (ECG) at screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Apremilast 20 mg BID/ 30 mg BID

    Apremilast 20 mg or 30 mg orally twice per day

    Drug: Apremilast

Interventions

  • 20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.

    Also known as: Otezla, CC-10004

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Events (TEAEs) During the Treatment Phase

    TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event.

    Time frame: Week 0 to Week 12

  2. Treatment Emergent Adverse Events (TEAEs) During the Extension Phase

    TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event.

    Time frame: Week 12 to Week 24

Secondary outcomes

  1. Percentage of Participants With at Least a 1 Point Reduction on 0 to 5 Point Scale From Baseline in Static Physician Global Assessment (sPGA) at Week 12

    The static Physician's Global Assessment (sPGA) rated the investigator's overall clinical assessment of a participants plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Decreases in sPGA correspond to clinical improvement.

    Time frame: Baseline and Week 12

  2. Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12

    The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.

    Time frame: Baseline and Week 12

  3. Percentage of Participants Who Achieved a PASI-75 Score at Week 12

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 12. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant.

    Time frame: Baseline to Week 12

  4. Percentage of Participants Who Achieved a PASI-50 Score at Week 12

    PASI -50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 12. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant.

    Time frame: Baseline to Week 12

  5. Maximal PASI Response Documented for Each Participant During Treatment Phase

    PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.

    Time frame: Baseline to Week 12

  6. Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) Involvement at Week 12

    The BSA estimate was based on the palm area of the hand of the participant which equates to 1% of the total body surface area.

    Time frame: Baseline to Week 12

  7. Time to Clinically Relevant Response (Time to Achieve PASI-50) During Treatment Phase

    Time to clinically relevant response (time to achieve PASI-50) during treatment phase was not analyzed. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.

  8. Time to Achieve PASI-75 During Treatment Phase

    Time to achieve PASI-75 during treatment phase was not analyzed. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.

  9. Time to Relapse of Psoriasis (50% Loss of Maximal PASI Score Improvement in Participants Who Achieved at Least PASI-50 During the Treatment Phase) During the Observational Follow up Phase

    Time to relapse of psoriasis (50% loss of maximal PASI score improvement in participants who achieved at least PASI-50 during the treatment phase) during the observational follow up phase was not analyzed. Time to relapse of psoriasis was defined as a 50% loss of maximal PASI score improvement in participants who achieved at least PASI-50 during the treatment or extension phase. The lesion on each area of the body was assessed for redness, thickness, and scaling.

    Time frame: 28-day Observational Follow-up Phase; Days 168 to Day 196.

  10. Percent of Participants With Psoriatic Arthritis Who Achieved an American College of Rheumatology 20% Improvement (ACR-20) Response at Week 12

    A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

    Time frame: Baseline to Week 12

  11. Time to Relapse of Psoriatic Arthritis During the Observational Follow-up Phase

    A relapse was defined as a 50% loss of maximal American College of Rheumatoid (ACR) Score improvement in participants with psoriatic arthritis who achieved at least an ACR 20 score during the treatment phase. Relapses were only captured prior to the prescription of concomitant psoriatic treatment.

    Time frame: Observational follow up phase; Days 168 to Day 196

  12. Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12)

    Plasma concentrations of apremilast were determined using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS). For Day 1, AUC0-12 was calculated, using linear trapezoidal area method in WinNonlin (linear-linear trapezoidal). For Days 85 and 169/170, the AUC during a dosing interval (12 hours) (AUC0-12), was calculated at steady-state using the partial area function within WinNonlin. .

    Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose

  13. Peak (Maximum) Plasma Concentration of Medication (Cmax)

    The maximum observed plasma concentration of apremilast (Cmax); the maximum plasma concentration (Cmax) was obtained directly from the observed concentration-time data on Days 1, 85, and 169/170, respectively.

    Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose

  14. Trough Plasma Concentration (Cmin)

    The trough observed plasma concentration of apremilast (Cmin) was determined directly from the observed pre-AM dose concentration on Day 85.

    Time frame: Day 85 Pre-dose

  15. Time to Maximum Plasma Concentration (Tmax) During the Treatment Phase

    The time to reach Cmax (Tmax) was obtained directly from the observed concentration-time data on Day 85. Actual times utilized were used for reporting Tmax values.

    Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose

  16. Terminal Phase Elimination Half Life of Apremilast (t½)

    Terminal phase elimination half-life (t1/2) was calculated as follows: t1/2 = 0.693/λz. The terminal elimination rate constant (λZ) was estimated by linear regression of the log-transformed concentration-time data.

    Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose

  17. Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CLz/F) During the Treatment Phase

    The apparent total clearance of apremilast from plasma after extravascular administration (CLz/F); for Day 1, apparent clearance of drug from plasma (CL/F) was not calculated. For Day 85, Apparent clearance of drug from plasma after extravascular administration (CL/F) was calculated as follows: CL/F= Dose/AUC\^12 where τ=12.

    Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose

  18. Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Treatment Phase

    Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) (for Days 1, 85, and 169/170) 1. For Day 1, Vz/F was not calculated. 2. For Days 85 and 169/170, apparent volume of distribution of drug (V/z) based on the terminal phase was calculated as follows: Vz/F=Dose/(λ\*AUC\^12)

    Time frame: Day 85

  19. Accumulation Index (R)

    Accumulation represents the relationship between the dosing interval and the rate of elimination for the drug.

    Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose

  20. Mean Residence Time (MRT) During the Treatment Phase

    Mean Residence Time (MRT) is defined as the mean duration of time the drug spends in the body. The average concentration at steady state (Cavg) (for Day 85 was calculated as follows: Cavg = (Day 85 AUC0-12)/(12).

    Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose

  21. Change From Baseline in Peripheral Blood T Cell, B Cell, and NK Cell Subsets at Week 12

    T cells or T lymphocytes, a type of white blood cell, play a role in cell-mediated immunity. T cells are distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on the cell surface and mature in the thymus. B cells, a type of lymphocyte in the humoral immunity of the adaptive immune system can be distinguished by the presence of a protein on the B cells outer surface called a B cell receptor (BCR). This receptor protein allows a B cell to bind to a specific antigen and make antibodies against antigens \[(antigen-presenting cells APCs)\], and to develop into memory B cells after activation by antigen interaction. Natural Killer Cells (NK) are a type of cytotoxic lymphocyte critical to the innate immune system. Their role is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. They constitute the third kind of cells differentiated from the common lymphoid progenitor generating B and T lymphocytes and mature in the bone marrow.

    Time frame: Baseline and Week 12

  22. Percent Change From Baseline of CD3 in the Dermis of the Psoriatic Skin Biopsy at Week 12

    The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

    Time frame: Baseline and Week 12

  23. Percent Change From Baseline of CD3 in the Epidermis of the Psoriatic Skin Biopsy at Week 12

    The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

    Time frame: Baseline and Week 12

  24. Percent Change From Baseline of CD 11c in the Dermis of the Psoriatic Skin Biopsy at Week 12

    The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

    Time frame: Baseline and Week 12

  25. Percent Change From Baseline of CD11c in the Epidermis of the Psoriatic Skin Biopsy at Week 12

    The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

    Time frame: Baseline and Week 12

  26. Percent Change From Baseline of CD56 in the Dermis of the Psoriatic Skin Biopsy at Week 12

    The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

    Time frame: Baseline and Week 12

  27. Percent Change From Baseline of CD56 in the Epidermis of the Psoriatic Skin Biopsy at Week 12

    The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

    Time frame: Baseline and Week 12

  28. Percent Change From Baseline of Langerin in the Dermis of Psoriatic Skin Biopsy at Week 12

    The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

    Time frame: Baseline and Week 12

  29. Percent Change From Baseline of Langerin in the Epidermis of the Psoriatic Skin Biopsy at Week 12

    The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

    Time frame: Baseline and Week 12

  30. Percent Change From Baseline of Epidermal Thickness in the Psoriatic Skin Biopsy at Week 12

    The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

    Time frame: Baseline and Week 12

  31. Percent Change From Baseline in the Inducible Nitric Oxide (iNOS) Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  32. Percent Change From Baseline in the Interleukin (IL) IL-22 Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  33. Percent Change From Baseline in the p40 Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  34. Percent Change From Baseline in the Defensin Beta 4 (DEFB4) Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) i being measured.

    Time frame: Baseline and Week 12

  35. Percent Change From Baseline in the keratin16 (K16) Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  36. Percent Change From Baseline in the pluripotent19 (P19) Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  37. Percent Change From Baseline in the IL8 Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  38. Percent Change From Baseline in the MX1 (Gene That Encodes the Interferon-induced p78 Protein) Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  39. Percent Change From Baseline in the IL17A Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  40. Percent Change From Baseline in the Tumor Necrosing Factor (TNF) Alpha Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Week 0 to Week 12

  41. Percent Change From Baseline in the Interferon (INF) Gamma Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  42. Percent Change From Baseline in the IL10 Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  43. Percent Change From Baseline in the Chemokine Ligand (CXCL9) Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  44. Percent Change From Baseline in the IL2 Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  45. Percent Change From Baseline in the Dendritic Cell (CD83) Inflammatory Marker in Psoriatic Skin Biopsies

    Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

    Time frame: Baseline and Week 12

  46. Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 12

    DLQI was the dermatology-specific quality of life (QOL) measure used for the psoriatic population. The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on a participants QoL, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Possible responses for each of the 10 items are: not at all, a little, a lot, and very much. Each question is rated on a scale of 0 to 3 with a total range of 0 to 30. Higher scores indicate greater impact of disease on QOL

    Time frame: Baseline to Week 12

  47. Change From Baseline in the Medical Outcome Study Short Form 36-item Health Survey (SF-36) Scores, Mental and Physical Components to Week 12

    The SF-36 was a self-administered instrument consisting of 8 multi-item scales that assess 8 health domains: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. A higher score post-baseline is indicative of improvement in the disease state. The summary physical health score included physical functioning, role-physical, bodily pain and general health. The summary mental health score included: vitality, social functioning, role-emotional and mental health. The resulting score for each subscale is then standardized, to obtain values ranging from 0 to 100, with higher values indicating a better QOL.

    Time frame: Baseline to Week 12

  48. Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12) During the Extension Phase

    Plasma concentrations of apremilast were determined using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS).

    Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose

  49. Peak (Maximum) Plasma Concentration of Apremilast (Cmax) During the Extension Phase

    The maximum observed plasma concentration of CC-10004 (Cmax); the maximum plasma concentration (Cmax) was obtained directly from the observed concentration-time data on Days 169/170.

    Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose

  50. Time to Maximum Plasma Concentration (Tmax) During the Extension Phase

    The time to reach Cmax (Tmax) was obtained directly from the observed concentration-time data on Day 169/170. Actual times utilized were used for reporting Tmax values.

    Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose

  51. Terminal Phase Elimination Half Life of Apremilast (t½) During the Extension Phase

    Terminal phase elimination half-life (t1/2) was calculated as follows: t1/2 = 0.693/λz. The terminal elimination rate constant (λZ) was estimated by linear regression of the log-transformed concentration-time data.

    Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose

  52. Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CL/F) During the Extension Phase

    For 169/170, apparent clearance of drug from plasma after extravascular administration (CL/F) was calculated as follows: CL/F= Dose/AUC12

    Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose

  53. Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Extension Phase

    For Days 169/170, apparent volume of distribution of drug (V/z) based on the terminal phase was calculated as follows: Vz/F=Dose/(λ\*AUC12) where λ = the terminal elimination rate constant

    Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose

  54. Accumulation Index During the Extension Phase

    Accumulation represents the relationship between the dosing interval and the rate of elimination for the drug.

    Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose

  55. Mean Residence Time (MRT) During the Extension Phase

    Mean Residence Time (MRT) is defined as the mean duration of time the drug spends in the body. The average concentration at steady state (Cavg) (for Days169/170) was calculated as follows: Cavg = (Day 169/170)/(12)

    Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose

07

Results

Posted Oct 21, 2014

Participant flow

Participants must have had a diagnosis of plaque-type psoriasis for at least 6 months and had an insufficient response, were unresponsive, intolerant of, or had medical contraindications to standard systemic therapy or biological treatment for plaque-type psoriasis. The study was conducted at 4 sites in the U.S. from 20 August 2007 to 12 May 2009.

Treatment Phase
Participant flow — Treatment Phase
MilestoneApremilast 20mgApremilast 20mg/20mgApremilast 20mg/30mg
Started3100
Received apremilast3000
Completed1900
Not completed1200
Withdrew: Adverse event200
Withdrew: Intolerability to study drug200
Withdrew: Lack of efficacy300
Withdrew: Withdrawal by subject300
Withdrew: Lost to follow-up100
Withdrew: Protocol violation100
Treatment Extension Phase
Participant flow — Treatment Extension Phase
MilestoneApremilast 20mgApremilast 20mg/20mgApremilast 20mg/30mg
Started047
Completed044
Not completed003
Withdrew: Withdrawal by subject002
Withdrew: Death001
Observational Follow Up Phase
Participant flow — Observational Follow Up Phase
MilestoneApremilast 20mgApremilast 20mg/20mgApremilast 20mg/30mg
Started1444
Completed1444
Not completed000

Outcome measures

PrimaryTreatment Emergent Adverse Events (TEAEs) During the Treatment Phase

TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event.

Time frame:
Week 0 to Week 12
Reported as:
Number · participants
Treatment Emergent Adverse Events (TEAEs) During the Treatment Phase
participantsApremilast 20 mg
≥ 1 AE25
≥ 1 AE with a suspected relationship to study drug13
≥ 1 severe AE3
≥ 1Severe AE suspected to be related to study drug1
≥ 1 SAE0
≥ AE leading to study drug discontinuation4
>=1 treatment-related AE drug discontinued2
SecondaryPercentage of Participants With at Least a 1 Point Reduction on 0 to 5 Point Scale From Baseline in Static Physician Global Assessment (sPGA) at Week 12

The static Physician's Global Assessment (sPGA) rated the investigator's overall clinical assessment of a participants plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Decreases in sPGA correspond to clinical improvement.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 1 Point Reduction on 0 to 5 Point Scale From Baseline in Static Physician Global Assessment (sPGA) at Week 12
percentage of participantsApremilast 20 mg PO BID (Treatment Phase)
Percentage of Participants With at Least a 1 Point Reduction on 0 to 5 Point Scale From Baseline in Static Physician Global Assessment (sPGA) at Week 1266.7 (47.2 to 82.7)
SecondaryPercent Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12

The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.

Time frame:
Baseline and Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12
percent changeApremilast 20 mg
Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12-59.0 ± 31.59
SecondaryPercentage of Participants Who Achieved a PASI-75 Score at Week 12

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 12. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI-75 Score at Week 12
percentage of participantsApremilast 20 mg
Percentage of Participants Who Achieved a PASI-75 Score at Week 1230.00 (14.7 to 49.4)
SecondaryPercentage of Participants Who Achieved a PASI-50 Score at Week 12

PASI -50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 12. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI-50 Score at Week 12
percentage of participantsApremilast 20 mg
Percentage of Participants Who Achieved a PASI-50 Score at Week 1246.7 (28.3 to 65.7)
SecondaryMaximal PASI Response Documented for Each Participant During Treatment Phase

PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.

Time frame:
Baseline to Week 12

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) Involvement at Week 12

The BSA estimate was based on the palm area of the hand of the participant which equates to 1% of the total body surface area.

Time frame:
Baseline to Week 12
Reported as:
Mean · Percent change in BSA
Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) Involvement at Week 12
Percent change in BSAApremilast 20 mg
Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) Involvement at Week 12-53.0 ± 35.50
SecondaryTime to Clinically Relevant Response (Time to Achieve PASI-50) During Treatment Phase

Time to clinically relevant response (time to achieve PASI-50) during treatment phase was not analyzed. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.

No measurements were reported for this outcome.

SecondaryTime to Achieve PASI-75 During Treatment Phase

Time to achieve PASI-75 during treatment phase was not analyzed. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.

No measurements were reported for this outcome.

SecondaryTime to Relapse of Psoriasis (50% Loss of Maximal PASI Score Improvement in Participants Who Achieved at Least PASI-50 During the Treatment Phase) During the Observational Follow up Phase

Time to relapse of psoriasis (50% loss of maximal PASI score improvement in participants who achieved at least PASI-50 during the treatment phase) during the observational follow up phase was not analyzed. Time to relapse of psoriasis was defined as a 50% loss of maximal PASI score improvement in participants who achieved at least PASI-50 during the treatment or extension phase. The lesion on each area of the body was assessed for redness, thickness, and scaling.

Time frame:
28-day Observational Follow-up Phase; Days 168 to Day 196.

No measurements were reported for this outcome.

SecondaryPercent of Participants With Psoriatic Arthritis Who Achieved an American College of Rheumatology 20% Improvement (ACR-20) Response at Week 12

A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percent of Participants With Psoriatic Arthritis Who Achieved an American College of Rheumatology 20% Improvement (ACR-20) Response at Week 12
percentage of participantsApremilast 20 mg PO BID (Treatment Phase)
Percent of Participants With Psoriatic Arthritis Who Achieved an American College of Rheumatology 20% Improvement (ACR-20) Response at Week 1225.0
SecondaryTime to Relapse of Psoriatic Arthritis During the Observational Follow-up Phase

A relapse was defined as a 50% loss of maximal American College of Rheumatoid (ACR) Score improvement in participants with psoriatic arthritis who achieved at least an ACR 20 score during the treatment phase. Relapses were only captured prior to the prescription of concomitant psoriatic treatment.

Time frame:
Observational follow up phase; Days 168 to Day 196

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12)

Plasma concentrations of apremilast were determined using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS). For Day 1, AUC0-12 was calculated, using linear trapezoidal area method in WinNonlin (linear-linear trapezoidal). For Days 85 and 169/170, the AUC during a dosing interval (12 hours) (AUC0-12), was calculated at steady-state using the partial area function within WinNonlin. .

Time frame:
Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12)
ng*hr/mLApremilast 20mg
Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12)2424.48 ± 46.87
SecondaryPeak (Maximum) Plasma Concentration of Medication (Cmax)

The maximum observed plasma concentration of apremilast (Cmax); the maximum plasma concentration (Cmax) was obtained directly from the observed concentration-time data on Days 1, 85, and 169/170, respectively.

Time frame:
Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Reported as:
Geometric mean · ng/mL
Peak (Maximum) Plasma Concentration of Medication (Cmax)
ng/mLApremilast 20mg
Peak (Maximum) Plasma Concentration of Medication (Cmax)364.85 ± 38.25
SecondaryTrough Plasma Concentration (Cmin)

The trough observed plasma concentration of apremilast (Cmin) was determined directly from the observed pre-AM dose concentration on Day 85.

Time frame:
Day 85 Pre-dose
Reported as:
Geometric mean · ng/mL
Trough Plasma Concentration (Cmin)
ng/mLApremilast 20mg
Trough Plasma Concentration (Cmin)101.36 ± 71.6
SecondaryTime to Maximum Plasma Concentration (Tmax) During the Treatment Phase

The time to reach Cmax (Tmax) was obtained directly from the observed concentration-time data on Day 85. Actual times utilized were used for reporting Tmax values.

Time frame:
Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) During the Treatment Phase
hoursApremilast 20mg
Time to Maximum Plasma Concentration (Tmax) During the Treatment Phase2.00 (1.00 to 4.03)
SecondaryTerminal Phase Elimination Half Life of Apremilast (t½)

Terminal phase elimination half-life (t1/2) was calculated as follows: t1/2 = 0.693/λz. The terminal elimination rate constant (λZ) was estimated by linear regression of the log-transformed concentration-time data.

Time frame:
Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Reported as:
Geometric mean · Liters
Terminal Phase Elimination Half Life of Apremilast (t½)
LitersApremilast 20mg
Terminal Phase Elimination Half Life of Apremilast (t½)7.832 ± 26.031
SecondaryApparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CLz/F) During the Treatment Phase

The apparent total clearance of apremilast from plasma after extravascular administration (CLz/F); for Day 1, apparent clearance of drug from plasma (CL/F) was not calculated. For Day 85, Apparent clearance of drug from plasma after extravascular administration (CL/F) was calculated as follows: CL/F= Dose/AUC\^12 where τ=12.

Time frame:
Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Reported as:
Geometric mean · mL/hour
Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CLz/F) During the Treatment Phase
mL/hourApremilast 20mg
Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CLz/F) During the Treatment Phase8249.19 ± 46.87
SecondaryApparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Treatment Phase

Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) (for Days 1, 85, and 169/170) 1. For Day 1, Vz/F was not calculated. 2. For Days 85 and 169/170, apparent volume of distribution of drug (V/z) based on the terminal phase was calculated as follows: Vz/F=Dose/(λ\*AUC\^12)

Time frame:
Day 85
Reported as:
Geometric mean · mL
Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Treatment Phase
mLApremilast 20mg
Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Treatment Phase107616.08 ± 47.03
SecondaryAccumulation Index (R)

Accumulation represents the relationship between the dosing interval and the rate of elimination for the drug.

Time frame:
Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Reported as:
Geometric mean · ratio
Accumulation Index (R)
ratioApremilast 20mg
Accumulation Index (R)1.68 ± 53.17
SecondaryMean Residence Time (MRT) During the Treatment Phase

Mean Residence Time (MRT) is defined as the mean duration of time the drug spends in the body. The average concentration at steady state (Cavg) (for Day 85 was calculated as follows: Cavg = (Day 85 AUC0-12)/(12).

Time frame:
Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Reported as:
Geometric mean · hours
Mean Residence Time (MRT) During the Treatment Phase
hoursApremilast 20mg PO BID
Mean Residence Time (MRT) During the Treatment Phase202.04 ± 46.87
SecondaryChange From Baseline in Peripheral Blood T Cell, B Cell, and NK Cell Subsets at Week 12

T cells or T lymphocytes, a type of white blood cell, play a role in cell-mediated immunity. T cells are distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on the cell surface and mature in the thymus. B cells, a type of lymphocyte in the humoral immunity of the adaptive immune system can be distinguished by the presence of a protein on the B cells outer surface called a B cell receptor (BCR). This receptor protein allows a B cell to bind to a specific antigen and make antibodies against antigens \[(antigen-presenting cells APCs)\], and to develop into memory B cells after activation by antigen interaction. Natural Killer Cells (NK) are a type of cytotoxic lymphocyte critical to the innate immune system. Their role is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. They constitute the third kind of cells differentiated from the common lymphoid progenitor generating B and T lymphocytes and mature in the bone marrow.

Time frame:
Baseline and Week 12
Reported as:
Mean · percentage of lymphocytes
Change From Baseline in Peripheral Blood T Cell, B Cell, and NK Cell Subsets at Week 12
percentage of lymphocytesApremilast 20 mg PO BID (Treatment Phase)
CD 16 + CD 56 (NK cells)-0.7 ± 3.05
CD 19 (B-cells)-0.5 ± 2.63
CD 3 (T-cells)0.6 ± 2.63
SecondaryPercent Change From Baseline of CD3 in the Dermis of the Psoriatic Skin Biopsy at Week 12

The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline of CD3 in the Dermis of the Psoriatic Skin Biopsy at Week 12
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline of CD3 in the Dermis of the Psoriatic Skin Biopsy at Week 12-62.0 (-84.3 to 290.9)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.013
SecondaryPercent Change From Baseline of CD3 in the Epidermis of the Psoriatic Skin Biopsy at Week 12

The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline of CD3 in the Epidermis of the Psoriatic Skin Biopsy at Week 12
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline of CD3 in the Epidermis of the Psoriatic Skin Biopsy at Week 12-47.4 (-100.0 to 159.5)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.074
SecondaryPercent Change From Baseline of CD 11c in the Dermis of the Psoriatic Skin Biopsy at Week 12

The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline of CD 11c in the Dermis of the Psoriatic Skin Biopsy at Week 12
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline of CD 11c in the Dermis of the Psoriatic Skin Biopsy at Week 12-54.6 (-88.8 to 284)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.018
SecondaryPercent Change From Baseline of CD11c in the Epidermis of the Psoriatic Skin Biopsy at Week 12

The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline of CD11c in the Epidermis of the Psoriatic Skin Biopsy at Week 12
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline of CD11c in the Epidermis of the Psoriatic Skin Biopsy at Week 12-88.6 (-100.0 to 46.3)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.001
SecondaryPercent Change From Baseline of CD56 in the Dermis of the Psoriatic Skin Biopsy at Week 12

The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline of CD56 in the Dermis of the Psoriatic Skin Biopsy at Week 12
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline of CD56 in the Dermis of the Psoriatic Skin Biopsy at Week 12-12.5 (-68.9 to 57.1)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.632
SecondaryPercent Change From Baseline of CD56 in the Epidermis of the Psoriatic Skin Biopsy at Week 12

The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline of CD56 in the Epidermis of the Psoriatic Skin Biopsy at Week 12
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline of CD56 in the Epidermis of the Psoriatic Skin Biopsy at Week 12-73.3 (-100.0 to 311.1)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.242
SecondaryPercent Change From Baseline of Langerin in the Dermis of Psoriatic Skin Biopsy at Week 12

The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline of Langerin in the Dermis of Psoriatic Skin Biopsy at Week 12
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline of Langerin in the Dermis of Psoriatic Skin Biopsy at Week 12-57.9 (-100.0 to 178.3)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.329
SecondaryPercent Change From Baseline of Langerin in the Epidermis of the Psoriatic Skin Biopsy at Week 12

The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline of Langerin in the Epidermis of the Psoriatic Skin Biopsy at Week 12
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline of Langerin in the Epidermis of the Psoriatic Skin Biopsy at Week 1217.1 (-78.7 to 300.0)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.130
SecondaryPercent Change From Baseline of Epidermal Thickness in the Psoriatic Skin Biopsy at Week 12

The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline of Epidermal Thickness in the Psoriatic Skin Biopsy at Week 12
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline of Epidermal Thickness in the Psoriatic Skin Biopsy at Week 12-34.3 (-65.4 to 42.2)
SecondaryPercent Change From Baseline in the Inducible Nitric Oxide (iNOS) Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the Inducible Nitric Oxide (iNOS) Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the Inducible Nitric Oxide (iNOS) Inflammatory Marker in Psoriatic Skin Biopsies-100.0 (-100.0 to 55.9)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.008
SecondaryPercent Change From Baseline in the Interleukin (IL) IL-22 Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the Interleukin (IL) IL-22 Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the Interleukin (IL) IL-22 Inflammatory Marker in Psoriatic Skin Biopsies-100.0 (-100.0 to -44.5)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.031
SecondaryPercent Change From Baseline in the p40 Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the p40 Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the p40 Inflammatory Marker in Psoriatic Skin Biopsies-86.7 (-100.0 to 51.7)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.039
PrimaryTreatment Emergent Adverse Events (TEAEs) During the Extension Phase

TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event.

Time frame:
Week 12 to Week 24
Reported as:
Number · participants
Treatment Emergent Adverse Events (TEAEs) During the Extension Phase
participantsApremilast 20mg/20mg (Extension Phase)Apremilast 20mg/30mg (Extension Phase)
≥ 1 AE45
≥ 1 AE with a suspected relationship to study drug02
≥ 1 severe AE11
≥ 1 SAE01
SecondaryPercent Change From Baseline in the Defensin Beta 4 (DEFB4) Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) i being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the Defensin Beta 4 (DEFB4) Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the Defensin Beta 4 (DEFB4) Inflammatory Marker in Psoriatic Skin Biopsies-82.3 (-100.0 to 14.5)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.014
SecondaryPercent Change From Baseline in the keratin16 (K16) Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the keratin16 (K16) Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the keratin16 (K16) Inflammatory Marker in Psoriatic Skin Biopsies-78.6 (-99.9 to 217.7)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.015
SecondaryPercent Change From Baseline in the pluripotent19 (P19) Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the pluripotent19 (P19) Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the pluripotent19 (P19) Inflammatory Marker in Psoriatic Skin Biopsies-68.3 (-100.0 to 326.6)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.018
SecondaryPercent Change From Baseline in the IL8 Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the IL8 Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the IL8 Inflammatory Marker in Psoriatic Skin Biopsies-66.5 (-100.0 to 136.2)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.018
SecondaryPercent Change From Baseline in the MX1 (Gene That Encodes the Interferon-induced p78 Protein) Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the MX1 (Gene That Encodes the Interferon-induced p78 Protein) Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the MX1 (Gene That Encodes the Interferon-induced p78 Protein) Inflammatory Marker in Psoriatic Skin Biopsies-52.6 (-97.0 to -1.3)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryPercent Change From Baseline in the IL17A Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the IL17A Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the IL17A Inflammatory Marker in Psoriatic Skin Biopsies-49.4 (-100.0 to 76.8)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.031
SecondaryPercent Change From Baseline in the Tumor Necrosing Factor (TNF) Alpha Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Week 0 to Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the Tumor Necrosing Factor (TNF) Alpha Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the Tumor Necrosing Factor (TNF) Alpha Inflammatory Marker in Psoriatic Skin Biopsies-42.7 (-100.0 to 242.9)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.217
SecondaryPercent Change From Baseline in the Interferon (INF) Gamma Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the Interferon (INF) Gamma Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the Interferon (INF) Gamma Inflammatory Marker in Psoriatic Skin Biopsies-37.6 (-100.0 to 250.3)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.539
SecondaryPercent Change From Baseline in the IL10 Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the IL10 Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the IL10 Inflammatory Marker in Psoriatic Skin Biopsies-26.5 (-100.0 to 565.0)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.169
SecondaryPercent Change From Baseline in the Chemokine Ligand (CXCL9) Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the Chemokine Ligand (CXCL9) Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the Chemokine Ligand (CXCL9) Inflammatory Marker in Psoriatic Skin Biopsies-36.4 (-97.1 to 1021.2)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.339
SecondaryPercent Change From Baseline in the IL2 Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the IL2 Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the IL2 Inflammatory Marker in Psoriatic Skin Biopsies-25.0 (-100.0 to 875.7)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.898
SecondaryPercent Change From Baseline in the Dendritic Cell (CD83) Inflammatory Marker in Psoriatic Skin Biopsies

Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.

Time frame:
Baseline and Week 12
Reported as:
Median · percent change
Percent Change From Baseline in the Dendritic Cell (CD83) Inflammatory Marker in Psoriatic Skin Biopsies
percent changeApremilast 20 mg PO BID (Treatment Phase)
Percent Change From Baseline in the Dendritic Cell (CD83) Inflammatory Marker in Psoriatic Skin Biopsies14.2 (-98.5 to 162.1)
Statistical analysis
  • Apremilast 20 mg PO BID (Treatment Phase) · Wilcoxon (Mann-Whitney) · p = 0.622
SecondaryChange From Baseline in the Dermatology Life Quality Index (DLQI) at Week 12

DLQI was the dermatology-specific quality of life (QOL) measure used for the psoriatic population. The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on a participants QoL, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Possible responses for each of the 10 items are: not at all, a little, a lot, and very much. Each question is rated on a scale of 0 to 3 with a total range of 0 to 30. Higher scores indicate greater impact of disease on QOL

Time frame:
Baseline to Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 12
units on a scaleApremilast 20 mg PO BID (Treatment Phase)
Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 12-4.7 ± 8.66
SecondaryChange From Baseline in the Medical Outcome Study Short Form 36-item Health Survey (SF-36) Scores, Mental and Physical Components to Week 12

The SF-36 was a self-administered instrument consisting of 8 multi-item scales that assess 8 health domains: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. A higher score post-baseline is indicative of improvement in the disease state. The summary physical health score included physical functioning, role-physical, bodily pain and general health. The summary mental health score included: vitality, social functioning, role-emotional and mental health. The resulting score for each subscale is then standardized, to obtain values ranging from 0 to 100, with higher values indicating a better QOL.

Time frame:
Baseline to Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Medical Outcome Study Short Form 36-item Health Survey (SF-36) Scores, Mental and Physical Components to Week 12
units on a scaleApremilast 20 mg
Mental Component0.8 ± 7.45
Physical Component2.4 ± 7.64
SecondaryArea Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12) During the Extension Phase

Plasma concentrations of apremilast were determined using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS).

Time frame:
Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12) During the Extension Phase
ng*hr/mLApremilast 20/30mg BID
Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12) During the Extension Phase2019.71 ± 63.62
SecondaryPeak (Maximum) Plasma Concentration of Apremilast (Cmax) During the Extension Phase

The maximum observed plasma concentration of CC-10004 (Cmax); the maximum plasma concentration (Cmax) was obtained directly from the observed concentration-time data on Days 169/170.

Time frame:
Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Reported as:
Geometric mean · ng/mL
Peak (Maximum) Plasma Concentration of Apremilast (Cmax) During the Extension Phase
ng/mLApremilast 20mg/30mg PO BID (Treatment + Extension Phase)
Peak (Maximum) Plasma Concentration of Apremilast (Cmax) During the Extension Phase320.35 ± 47.64
SecondaryTime to Maximum Plasma Concentration (Tmax) During the Extension Phase

The time to reach Cmax (Tmax) was obtained directly from the observed concentration-time data on Day 169/170. Actual times utilized were used for reporting Tmax values.

Time frame:
Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Reported as:
Geometric mean · hours
Time to Maximum Plasma Concentration (Tmax) During the Extension Phase
hoursApremilast 20mg BID/30mg PO BID (Treatment + Extension Phase)
Time to Maximum Plasma Concentration (Tmax) During the Extension Phase1.59 ± 42
SecondaryTerminal Phase Elimination Half Life of Apremilast (t½) During the Extension Phase

Terminal phase elimination half-life (t1/2) was calculated as follows: t1/2 = 0.693/λz. The terminal elimination rate constant (λZ) was estimated by linear regression of the log-transformed concentration-time data.

Time frame:
Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Reported as:
Geometric mean · hours
Terminal Phase Elimination Half Life of Apremilast (t½) During the Extension Phase
hoursApremilast 20mg/30mg PO BID (Treatment + Extension Phase)
Terminal Phase Elimination Half Life of Apremilast (t½) During the Extension Phase6.287 ± 22.879
SecondaryApparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CL/F) During the Extension Phase

For 169/170, apparent clearance of drug from plasma after extravascular administration (CL/F) was calculated as follows: CL/F= Dose/AUC12

Time frame:
Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Reported as:
Geometric mean · mL/hour
Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CL/F) During the Extension Phase
mL/hourApremilast 20mg/30mg PO BID (Treatment + Extension Phase)
Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CL/F) During the Extension Phase14853.59 ± 63.62
SecondaryApparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Extension Phase

For Days 169/170, apparent volume of distribution of drug (V/z) based on the terminal phase was calculated as follows: Vz/F=Dose/(λ\*AUC12) where λ = the terminal elimination rate constant

Time frame:
Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Reported as:
Geometric mean · mL
Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Extension Phase
mLApremilast 20mg BID/30mg PO BID (Treatment + Extension Phase)
Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Extension Phase134734.60 ± 63.70
SecondaryAccumulation Index During the Extension Phase

Accumulation represents the relationship between the dosing interval and the rate of elimination for the drug.

Time frame:
Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose

No measurements were reported for this outcome.

SecondaryMean Residence Time (MRT) During the Extension Phase

Mean Residence Time (MRT) is defined as the mean duration of time the drug spends in the body. The average concentration at steady state (Cavg) (for Days169/170) was calculated as follows: Cavg = (Day 169/170)/(12)

Time frame:
Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Reported as:
Geometric mean · hours
Mean Residence Time (MRT) During the Extension Phase
hoursApremilast 20mg/30mg PO BID (Treatment + Extension Phase)
Mean Residence Time (MRT) During the Extension Phase168.3092 ± 63.6203

Adverse events

Collected over Days 1 to Day 196 visit; Adverse Events (AE) were reported from the first day of study drug treatment through the 28 day observational follow up period. Maximum exposure to study medication was 171 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apremilast 20 mg (Treatment Phase)—0/30 (0%)25/30 (83.3%)
Apremilast 20mg/20mg (Extension Phase)—0/4 (0%)4/4 (100%)
Apremilast 20mg/30mg (Extension Phase)—1/7 (14.3%)4/7 (57.1%)
Most frequent serious events
Most frequent serious events
EventApremilast 20 mg (Treatment Phase)Apremilast 20mg/20mg (Extension Phase)Apremilast 20mg/30mg (Extension Phase)
ARRHYTHMIACardiac disorders0/300/41/7
HYPERTENSIVE HEART DISEASECardiac disorders0/300/41/7
MYOCARDIAL INFARCTIONCardiac disorders0/300/41/7
Most frequent other events
Showing 10 of 28
Most frequent other events
EventApremilast 20 mg (Treatment Phase)Apremilast 20mg/20mg (Extension Phase)Apremilast 20mg/30mg (Extension Phase)
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders0/300/42/7
EPISTAXISRespiratory, thoracic and mediastinal disorders1/300/42/7
NASOPHARYNGITISInfections and infestations1/301/41/7
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations1/301/40/7
NECK PAINMusculoskeletal and connective tissue disorders0/301/40/7
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/301/40/7
INFLUENZA LIKE ILLNESSGeneral disorders1/301/40/7
OEDEMA PERIPHERALGeneral disorders0/301/40/7
PRODUCTIVE COUGHRespiratory, thoracic and mediastinal disorders1/301/40/7
CORNEAL ABRASIONInjury, poisoning and procedural complications0/301/40/7

Baseline characteristics

Safety population consisted of all participants who were enrolled and received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Apremilast 20 mg (Treatment Phase)
Mean46.3 ± 11.43
Sex: Female, Male
Sex: Female, Male(Participants)Apremilast 20 mg (Treatment Phase)
Female11
Male19
Recalcitrant Psoriasis History
Recalcitrant Psoriasis History(years)Apremilast 20 mg (Treatment Phase)
Mean10.9 ± 11.36
Mean Psoriasis Area and Severity Index (PASI) Score
Mean Psoriasis Area and Severity Index (PASI) Score(units on a scale)Apremilast 20 mg (Treatment Phase)
Mean17.0 ± 6.77
Mean Body Surface Area (BSA) Involvement
Mean Body Surface Area (BSA) Involvement(Percentage of BSA)Apremilast 20 mg (Treatment Phase)
Mean22.4 ± 13.85
08

Study locations

4 sites
  • Tufts-New England Medical Center Hospitals
    Boston, Massachusetts 02111, United States
  • Central Dermatology
    Saint Louis, Missouri 63117, United States
  • Oregon Medical Research Center, P.C.
    Portland, Oregon 97223, United States
  • Baylor Research Institute
    Dallas, Texas 75246-1613, United States
09

References and documents

Publications

  • Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013 Aug;12(8):888-97. PubMed 23986162 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2007 to primary completion in Apr 2009, 20 months.

Results were first posted in Oct 2014, 5 years 6 months after primary completion. A results delay was requested in Aug 2010.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 20 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2007
First posted
Aug 27, 2007
StartActual
Aug 1, 2007
Primary completionActual
Apr 1, 2009
CompletionActual
May 1, 2009
Results delay requested
Aug 24, 2010
Results first posted
Oct 21, 2014
Last update
May 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00521339
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 27, 2007
Start date
Aug 1, 2007
Primary completion
Apr 1, 2009
Completion
May 1, 2009
Results posted
Oct 21, 2014
Last update
May 7, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion